acrivon therapeutics is a biotech company specializing in drug development through early clinical treatment success using our unique predictive biomarker approach. our technology platform is based on integrating drug-regulated, global proteomics with focused intact tissue digital imaging to develop drug-tailored biomarker signatures for prospective patient responder identification. the foundational science is based on proven, pathway-based methods linking active disease-driving mechanisms with the drug mechanism-of-action, to precisely match the therapy with patients who will benefit. our method is applicable across drug modalities
Company profile
Ticker
ACRV
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1.Acrivon AB • 2.Acrivon Securities Corporation ...
ACRV stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Results of Operations and Financial Condition
24 Apr 24
S-3
Shelf registration
17 Apr 24
8-K
Acrivon Therapeutics Announces $130 Million Private Placement Financing
9 Apr 24
S-8
Registration of securities for employees
29 Mar 24
8-K
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
4 Mar 24
Latest ownership filings
4
Mary Miller
19 Apr 24
4
Rajeev M. Shah
15 Apr 24
4
JOSEPH EDELMAN
15 Apr 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
15 Apr 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
11 Apr 24
4
Santhosh Palani
6 Mar 24
3
Santhosh Palani
6 Mar 24
4
Mary Miller
16 Feb 24
4
Kristina Masson
16 Feb 24
4
Rasmus Holm-Jorgensen
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 30.27 mm | 30.27 mm | 30.27 mm | 30.27 mm | 30.27 mm | 30.27 mm |
Cash burn (monthly) | 2.74 mm | 183.17 k | 5.38 mm | 4.67 mm | (no burn) | 919.33 k |
Cash used (since last report) | 18.96 mm | 1.27 mm | 37.25 mm | 32.31 mm | n/a | 6.37 mm |
Cash remaining | 11.31 mm | 29.00 mm | -6.98 mm | -2.04 mm | n/a | 23.90 mm |
Runway (months of cash) | 4.1 | 158.3 | -1.3 | -0.4 | n/a | 26.0 |
Institutional ownership, Q3 2023
70.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 46 |
Opened positions | 4 |
Closed positions | 1 |
Increased positions | 15 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 144.21 bn |
Total shares | 21.83 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 4.81 mm | $45.99 bn |
Chione | 3.86 mm | $60.63 mm |
Perceptive Advisors | 3.01 mm | $28.76 bn |
Sands Capital Life Sciences Pulse Fund II | 1.65 mm | $27.50 mm |
Sands Capital Ventures | 1.65 mm | $15.80 bn |
Citadel Advisors | 1.65 mm | $15.78 bn |
Marshall Wace North America | 1.22 mm | $0.00 |
Wellington Management | 888.13 k | $8.49 bn |
Marshall Wace | 597.47 k | $5.71 bn |
BLK Blackrock | 528.76 k | $5.05 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Apr 24 | Mary Miller | Common Stock | Payment of exercise | Dispose F | No | No | 10.34 | 558 | 5.77 k | 39,893 |
11 Apr 24 | Perceptive Advisors | Common Stock | Buy | Acquire P | Yes | No | 8.5 | 2,353,000 | 20.00 mm | 5,360,858 |
11 Apr 24 | Ra Capital Management | Common Stock | Grant | Acquire A | Yes | No | 8.5 | 3,530,000 | 30.01 mm | 7,914,206 |
4 Mar 24 | Santhosh Palani | Stock Option Common Stock | Grant | Acquire A | No | No | 5.05 | 32,500 | 164.13 k | 32,500 |
News
BMO Capital Maintains Outperform on Acrivon Therapeutics, Raises Price Target to $25
26 Apr 24
JMP Securities Maintains Market Outperform on Acrivon Therapeutics, Raises Price Target to $17
25 Apr 24
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $20 Price Target
25 Apr 24
Acrivon Therapeutics Reports Initial Positive Clinical Data For ACR-368 And Pipeline Program Progress Today At Corporate R&D Event
24 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
24 Apr 24
Press releases
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
24 Apr 24
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
16 Apr 24
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
10 Apr 24
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
8 Feb 24